Detalles de la búsqueda
1.
Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
Cancer;
130(11): 1930-1939, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38340349
2.
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Lancet;
401(10379): 821-832, 2023 03 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36774933
3.
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
J Natl Compr Canc Netw;
22(1): 4-16, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38394781
4.
Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters.
Oncologist;
28(3): 246-251, 2023 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36651837
5.
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab.
Oncologist;
28(6): 501-509, 2023 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36866412
6.
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Cancer;
128(11): 2085-2097, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35383908
7.
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw;
20(1): 71-90, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34991070
8.
Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Oncologist;
26(11): e2002-e2012, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34327774
9.
A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma.
Oncologist;
26(3): 182-e361, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33289953
10.
The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
Oncologist;
26(7): e1205-e1215, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33955118
11.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med;
378(14): 1277-1290, 2018 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29562145
12.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Cancer;
126(18): 4156-4167, 2020 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32673417
13.
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
Invest New Drugs;
38(4): 1108-1116, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31654285
14.
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma.
Invest New Drugs;
38(6): 1807-1814, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32472319
15.
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
J Natl Compr Canc Netw;
18(9): 1160-1170, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32886895
16.
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Lancet Oncol;
20(2): 297-310, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30658932
17.
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Lancet Oncol;
20(4): 581-590, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30827746
18.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Lancet Oncol;
20(10): 1370-1385, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31427204
19.
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.
J Natl Compr Canc Netw;
17(11): 1278-1285, 2019 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31693980
20.
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Lancet Oncol;
19(3): 405-415, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29439857